Cero Therapeutics announces critical patent application allowances from USPTO

CERo Therapeutics (CERO) announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office, USPTO, which materially expands the Company’s intellectual property portfolio. Patent Application No. 17/040,472, titled, “CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,” was allowed on March 13, 2025 and provides coverage for composition of matter and methods of use coverage for the Company’s lead compound, CER-1236. The allowed claims encompass the combination of a phosphatidylserine-targeting CD4+ CER-T cell with a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell, and their use to treat cancer. This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.